Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-06-07
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines, led by approved therapy CASGEVY and a pipeline spanning in vivo editing, cell therapy and siRNA.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved editing, second-franchise proof drives upside
The debate has shifted from whether gene editing works to whether one approved asset and one more owned franchise can support a durable commercial platform. The upside is meaningful, but the real bottlenecks are reimbursement, manufacturing cadence and clinical proof.

Analysis

Thesis
CRISPR Therapeutics has crossed the key science-validity hurdle with CASGEVY; the next five years are about turning that proof into a broader, partly owned commercial platform, with the stock rerating if one additional franchise becomes clinically and economically real.
Last Economy Alignment
AI helps target selection, construct design and portfolio triage, but value still clears through approvals, manufacturing and payer trust. This is a positive AI-era enabler, not a pure cognition winner.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.8x (from 5 most recent analyses)
Reasoning
The upside case is a transition from proof-of-science to proof-of-franchise. CASGEVY already gives real commercial validation and the balance sheet buys time, so CRISPR does not need every program to work. It needs CASGEVY to keep compounding and one owned branch, most likely cell therapy or cardiometabolic editing, to look commercially credible. That supports strong returns, but not a 10x-style outcome from today’s starting valuation.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is proof conversion beyond CASGEVY. If treatment throughput stays slower than hoped and H2 2026 through 2027 readouts fail to validate a second franchise, the market is likely to keep valuing the business as cash plus a partner-mediated approved asset rather than a broad platform. Regulatory timing, manufacturing readiness and value capture from partnered programs matter more than classic software commoditization risks.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.46
They control hard-to-copy gene-editing IP, regulatory know-how and a growing treatment-and-manufacturing playbook that should get stronger as more patients and programs run through it. AI helps them design faster, but approvals, supply and partner control still limit how much value they can keep.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$83.74
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case